Pharmaceuticals and biotechnology have come in the focus on the exchanges after Trump’s victory in the u.s. presidential election. The reason is mainly the opponent of Clinton’s seemingly harder line against the government during the election campaign – now believe the companies on a brighter future and investors hanging on.
Therefore, the initial public offering of Alligator Bioscience unusually well timed. The company, which develops immunaktiverande antikroppsläkemdel for tumörriktad immunotherapy is based in Lund, sweden, and started 15 years ago. Major shareholder since the start, is Stone and now is also the Investor in the ägarlistan.
It was eight years ago that the company began to focus on just immunonkologi, which means that they were early because it took only two to three years ago before the larger pharmaceutical companies began to latch on to just this research.
the Company now has a project portfolio that primarily consists of three drug candidates, of which one is already outlicensed to Janssen Biotech that exist within the Johnson & Johnson group. With successful clinical studies, the expected revenues in the future from J&J.
the Company makes in connection with the listing of a rights issue of approximately sek 350 million. At the checkout, are currently about the same and, therefore, is not this the money that is urgently needed to finance the current project portfolio. But the focus is on the further development after 2020 and that the company will further broaden its portfolio of drug candidates.
we all understand That is Alligators business is not about a few quick clips, but it will take several years before you will be able to see some results that can be used out on the market to help cancer patients.
however, It does mean that the Alligator becomes uninteresting as a share – on the contrary, the pharmaceutical market is in great need of new innovations that can provide new miljardsäljare when the old storsäljares patent expired and cheaper copies presses the profitability of the companies that once researched until the original drug.
It is evidently also the so-called ankarinvesterarna which is Catella, the sound and the Norron total invest 150 million at the introduction. And even for Private Shops this looks interesting – the company is inside the a whopping market and bioteknikaktier have been hot recently. Therefore, we believe in an initial rise for the Alligator after the listing.
the Price per share at the time of the introduction is 32,50 and minimum number that may be subscribed is 300 pieces. This is done at the Carnegie no later than 22 november, the day of or the day before with Avanza or Nordnet. The first listing date on the Nasdaq Stockholm is november 23.
No comments:
Post a Comment